Table 1.
Days post infection | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MyeloVec, % of original body weight | 100 | 94 | 90 | 90 | 91 | 92 | 95 | 96 | 95 | 95 | 95 | 95 | 91 | 91 | 94 |
100 | 97 | 94 | 93 | 92 | 98 | 101 | 103 | 104 | 101 | 102 | 101 | 102 | 104 | 103 | |
100 | 92 | 89 | 88 | 88 | 91 | 95 | 93 | 92 | 93 | 94 | 95 | 97 | 98 | 98 | |
100 | 94 | 90 | 89 | 89 | 91 | 91 | 87 | 91 | 94 | 96 | 98 | 98 | 99 | 98 | |
100 | 95 | 86 | 91 | 93 | 95 | 93 | 91 | 93 | 90 | 98 | 100 | 102 | 105 | 105 | |
pCCLchim-gp91phox-WPRE, % of original body weight | 100 | 91 | 85 | 78 | dead | ||||||||||
100 | 94 | 88 | 82 | dead | |||||||||||
100 | 98 | 95 | 99 | 96 | 98 | 102 | 103 | 102 | 100 | 102 | 102 | 103 | 106 | 106 | |
100 | 94 | 88 | 87 | 82 | 76 | dead | |||||||||
100 | 91 | 83 | 80 | dead | |||||||||||
Nontransduced CYBB−/− Lin− cells, % of original body weight |
100 | 88 | 84 | dead | |||||||||||
100 | 88 | dead | |||||||||||||
100 | 90 | 83 | dead | ||||||||||||
100 | 87 | 80 | dead | ||||||||||||
100 | 90 | 83 | dead | ||||||||||||
WT C57BL/6 Lin− cells, % of original body weight | 100 | 94 | 94 | 91 | 94 | 98 | 100 | 100 | 100 | 100 | 98 | 98 | 96 | 96 | 96 |
100 | 96 | 91 | 89 | 87 | 90 | 92 | 95 | 96 | 95 | 94 | 97 | 97 | 100 | 101 | |
100 | 94 | 93 | 98 | 97 | 102 | 104 | 102 | 103 | 102 | 99 | 97 | 96 | 98 | 98 | |
100 | 94 | 91 | 97 | 95 | 97 | 100 | 99 | 99 | 98 | 99 | 100 | 99 | 102 | 101 | |
100 | 98 | 99 | 99 | 98 | 103 | 103 | 103 | 102 | 108 | 97 | 98 | 98 | 98 | 100 | |
WT C57BL/6 (nontransplanted mice), % of original body weight |
100 | 100 | 98 | 103 | 100 | 103 | 101 | 99 | 100 | 97 | 100 | 98 | 100 | 100 | 99 |
100 | 96 | 96 | 100 | 97 | 96 | 95 | 95 | 99 | 98 | 95 | 94 | 97 | 98 | 97 | |
100 | 99 | 97 | 101 | 100 | 103 | 101 | 100 | 103 | 100 | 96 | 95 | 97 | 98 | 98 |